Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences

Summary

This phase I trial studies the side effects and best dose of olaparib when given with hyperthermia in treating patients with breast cancer that has come back in the chest wall. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hyperthermia treatment may kill or damage tumor cells by heating them to several degrees above normal body temperature. Giving olaparib and hyperthermia treatment may work better in treating patients with breast cancer that has come back in the chest well compared to standard of care.

Timeline

Start

2019-05-20

Primary completion

2021-08-26

Completion

2021-08-26

Drugs

Indications